Biohit Oyj: Notice pursuant to the Finnish Securities Markets Act, Chapter 9, Section 10
STOCK EXCHANGE RELEASE
June 8, 2018 at 3.30 PM
Biohit Oyj: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10
Biohit Oyj has received an announcement from Joel Suovaniemi on June 8, 2018 in accordance with the Finnish Securities Market Act Chapter 9, Section 5.
According to the announcement, the total number of Biohit Oyj voting rights owned by Joel Suovaniemi has decreased below five (5) per cent of all voting rights of Biohit Oyj on June 8, 2018.
Total positions of Joel Suovaniemi according to the notification:
|% of shares and voting rights ||% of shares and voting rights through financial instruments ||Total of both in %||Total number of shares and voting rights of issuer|
|Resulting situation on the date on which the threshold was crossed or reached||0||%||14 889 278 shares and |
71 423 778 votes
|Position of previous notification (if applicable)|
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: shares and voting rights:
|Class / type of shares|
|Number of shares and voting rights||% of shares and voting rights|
(SMA 9:6 and 9:7)
(SMA 9:6 ja 9:7)
B: Financial instruments according to SMA 9:6a
|Type of Financial instrument||Expiration date||Exercise / Conversion period||Physical or cash settlement||Number of shares and voting rights||% of shares and voting rights|
Information on the party obliged to give notice of major shareholding:
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
firstname.lastname@example.org, www.biohit .fi
Biohit Oyj in brief
Biohit Oyj is a Finnish biotechnology company operating on a global scale. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit’s headquarters are located in Helsinki with subsidiaries in Italy and the UK.